Tb treatment guidelines
Reading File
Searching the Web
TB tuberculosis treatment guidelines 2025 WHO
Finding Sources
Searching PubMed
"tuberculosis"[MeSH Terms] AND "drug therapy"[MeSH Terms]
Reading File
Reading File
Reading File
Reading Article
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
I now have comprehensive information to compose a detailed answer. Let me put it all together.
Tuberculosis (TB) Treatment Guidelines
Classification First
Before starting treatment, classify the case:
- Drug-susceptible TB (DS-TB) - susceptible to isoniazid (INH) + rifampicin (RIF)
- Latent TB Infection (LTBI) - infected but not active disease
- Drug-resistant TB - MDR, pre-XDR, XDR
- Special populations - HIV co-infection, pregnancy, pediatric, CNS/extrapulmonary
1. Drug-Susceptible Active TB (Pulmonary)
Treatment has two phases: an intensive phase and a continuation phase.
Standard 6-month Regimen (Preferred)
| Phase | Duration | Drugs | Frequency |
|---|---|---|---|
| Intensive | 8 weeks | HRZE (INH + RIF + PZA + EMB) | Daily (7 days/week) |
| Continuation | 18 weeks | HR (INH + RIF) | Daily (7 days/week) |
This is the preferred regimen per ATS/CDC/ERS/IDSA guidelines.
Alternative Continuation Schedules
| Option | Intensive Phase | Continuation Phase | Notes |
|---|---|---|---|
| 1 (Preferred) | HRZE daily x 8 wks | HR daily x 18 wks | Best |
| 2 | HRZE daily x 8 wks | HR 3x/week DOT x 18 wks | If less frequent DOT needed |
| 3 | HRZE 3x/week DOT x 8 wks | HR 3x/week DOT x 18 wks | Caution with HIV or cavitary disease |
| 4 | HRZE daily x 2 wks, then 2x/week x 6 wks | HR 2x/week DOT x 18 wks | Avoid in HIV or smear-positive/cavitary disease |
- Katzung's Basic & Clinical Pharmacology, 16th Ed.
- Tintinalli's Emergency Medicine, Comprehensive Study Guide
New 4-Month Regimen (2022/2025 Update)
A 4-month all-oral regimen is now recommended for eligible adults with pulmonary TB:
| Phase | Duration | Drugs |
|---|---|---|
| Intensive | 8 weeks | Rifapentine (RPT) + Moxifloxacin (MOX) + INH + PZA daily |
| Continuation | 9 weeks | RPT + MOX + INH daily |
- Non-inferior to the standard 6-month regimen for drug-susceptible pulmonary TB in persons age 12+ weighing at least 40 kg
- Recommended in the 2025 ATS/CDC/ERS/IDSA Practice Guideline [PMID: 40693952]
When to Prolong Treatment (beyond 6 months)
- Cavitary pulmonary TB with positive sputum culture at 2 months
- Immunocompromised patients (HIV, steroids)
- Extrapulmonary disease: CNS, skeletal, disseminated TB
- Drug-resistant TB
2. Latent TB Infection (LTBI)
Indicated for: recent TST/IGRA converters, close contacts of active cases, HIV-infected individuals, immunosuppressed patients.
| Regimen | Duration | Frequency | Notes |
|---|---|---|---|
| INH (isoniazid) | 9 months | Daily (5 mg/kg; max 300 mg) | Preferred in pregnancy (high-risk) |
| INH | 9 months | Twice weekly (DOT) (15 mg/kg; max 900 mg) | Must use DOT |
| INH | 6 months | Daily | Not for HIV+ or children |
| Rifampin (RIF) | 4 months | Daily (10 mg/kg; max 600 mg) | Good alternative, shorter |
| INH + Rifapentine (RPT) | 3 months | Once weekly (DOT or SAT) | Preferred short course |
| INH + RPT (1HP) | 1 month | Daily | HIV+ adults ≥13 yrs only |
Shorter courses (3HP, 4R) are preferred to improve adherence and completion rates.
- Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume, p. 938
- Tintinalli's Emergency Medicine
3. Drug-Resistant TB
INH Monoresistance (~8% globally)
- RIF + EMB + PZA + fluoroquinolone (moxifloxacin or levofloxacin) for 6 months
- Fluoroquinolone added because standard regimen alone has poorer outcomes
MDR-TB (resistant to INH + RIF)
Traditional approach: longer 18-24 month regimens with second-line agents. Now replaced by shorter all-oral regimens:
BPaL Regimen (FDA-approved August 2019):
- Bedaquiline + Pretomanid + Linezolid for 6 months (all-oral)
- Indicated for XDR-TB, treatment-intolerant or non-responsive MDR-TB
- 90% relapse-free cure in the Nix-TB trial
- Key toxicities: peripheral neuropathy (linezolid, >60% had treatment interruptions), QT prolongation (bedaquiline + pretomanid - both prolong QT, ECG monitoring required), elevated liver enzymes, anemia
BPaLM (Bedaquiline + Pretomanid + Linezolid + Moxifloxacin) - newer variant for pre-XDR TB per 2025 ATS/CDC/ERS/IDSA guidelines.
Recent systematic reviews confirm effectiveness of all-oral bedaquiline-based shorter regimens for drug-resistant TB [PMID: 40194835, 40172415].
- Murray & Nadel's Textbook of Respiratory Medicine
- Katzung's Basic & Clinical Pharmacology, 16th Ed.
4. HIV Co-infection
- TB treatment is the same regimen as HIV-negative patients
- Start ART within 2-8 weeks of starting TB treatment (unless TB meningitis - delay to 8 weeks)
- Watch for immune reconstitution inflammatory syndrome (IRIS) - paradoxical worsening after ART initiation
- Drug interactions: rifampin is a potent CYP inducer - may require ART regimen adjustment (prefer efavirenz-based ART)
- Patients with new TB diagnosis are ~20x more likely to have HIV; always test
5. Key Drug Adverse Effects
| Drug | Key Adverse Effects | Monitoring |
|---|---|---|
| INH | Hepatotoxicity (5-33%), peripheral neuropathy, SLE-like | LFTs in high-risk patients; give pyridoxine (B6) to prevent neuropathy |
| Rifampin | Hepatotoxicity, orange discoloration of body fluids, drug interactions (CYP inducer) | LFTs |
| Pyrazinamide (PZA) | Hepatotoxicity, hyperuricemia, gout | LFTs, uric acid |
| Ethambutol (EMB) | Optic neuritis (dose-related) - visual acuity and color vision changes | Monthly vision testing |
| Bedaquiline | QT prolongation, hepatotoxicity | ECG at baseline, monthly |
| Linezolid | Peripheral neuropathy, myelosuppression, serotonin syndrome | CBC, neurological assessment |
Stop anti-TB drugs if: AST >5x upper limit of normal, OR serum bilirubin >3 mg/dL.
6. Principles of TB Treatment
- Always use combination therapy - monotherapy causes resistance (resistant mutants present at ~1/10^5 bacteria; dual resistance at ~1/10^10)
- Direct Observed Therapy (DOT) - recommended for all intermittent regimens and mandatory for twice/thrice weekly dosing; key for compliance
- Drug susceptibility testing (DST) - modify therapy once results available
- Reportable disease - notify public health within 24 hours (in the US and most countries)
- Negative pressure isolation - for hospitalized patients with suspected active pulmonary TB
- Fixed-dose combinations - optimize effectiveness and prevent monotherapy errors
2025 Guideline Update (ATS/CDC/ERS/IDSA)
The 2025 joint practice guideline (PMID: 40693952) highlights:
- 4-month regimen (RPT-MOX-INH-PZA) now recommended for eligible adults and adolescents with pulmonary DS-TB
- Shortened 4-month regimen for children with nonsevere TB
- BPaL/BPaLM regimens (bedaquiline + pretomanid + linezolid ± moxifloxacin) recommended for drug-resistant TB
- All-oral, shorter regimens are the new standard for eligible patients
Make a ppt on this
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready! Here's the download link:
TB Treatment Guidelines
Presentation · PPTX
What's inside (11 slides):
| Slide | Content |
|---|---|
| 1 | Title slide - dark navy with amber accents |
| 2 | TB Classification & Approach (4 categories) |
| 3 | Standard 6-Month DS-TB Regimen (visual flow diagram) |
| 4 | Alternative Regimen Options (comparison table) |
| 5 | New 4-Month Regimen - 2025 ATS/CDC/ERS/IDSA update |
| 6 | LTBI Treatment - all 6 regimens with duration cards |
| 7 | Drug-Resistant TB (MDR/XDR) + BPaL regimen details |
| 8 | Key Drug Adverse Effects & Monitoring (all 6 drugs) |
| 9 | HIV Co-infection (epidemiology, regimen, ART timing, IRIS) |
| 10 | 6 Core Principles of TB Treatment |
| 11 | Key Takeaways + References |
The deck uses a deep navy / amber / teal medical color palette with consistent branding throughout.
This is a shared conversation. Sign in to Orris to start your own chat.